Integra Lifesciences Holdings (IART) EBITDA Margin (2009 - 2026)
Integra Lifesciences Holdings (IART) reported EBITDA Margin of 2.93% for Q1 2026, up 698.0% on a YoY basis from 0.37% in Q1 2025, and down 44.75% sequentially from 5.3% in Q4 2025.
Integra Lifesciences Holdings (IART) EBITDA Margin (2009 - 2026) Analysis & Trends
Integra Lifesciences Holdings (IART) has 18 years of EBITDA Margin data on file, last reported at 2.93% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin rose 698.0% year-over-year to 2.93%; the trailing twelve-month figure through Mar 2026 stood at 28.36% (down 2891.0% YoY), and the FY2025 full-year result was 30.17%, down 3194.0% from the prior year.
- EBITDA Margin declined to 2.93% in Q1 2026, from 5.3% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 17.04% in Q4 2022 to a low of 123.36% in Q2 2025.
- A 5-year average of 1.17% and a median of 5.3% in 2025 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin slumped 12263 bps in 2025 and surged 698 bps in 2026, its largest moves.
- Tracing IART's EBITDA Margin over 5 years: stood at 17.04% in 2022, then sank by 47 bps to 9.08% in 2023, then dropped by 11 bps to 8.05% in 2024, then tumbled by 34 bps to 5.3% in 2025, then tumbled by 45 bps to 2.93% in 2026.
- Business Quant data shows IART's EBITDA Margin at 2.93% in Q1 2026, 5.3% in Q4 2025, and 2.93% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 19.10% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 28.97% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 21.42% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 6.17% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 10.04% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Integra Lifesciences Holdings | 1.71 Bn | 1.45 Bn | 216.98 Mn | 2.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.93% |
| Dec 31, 2025 | 5.30% |
| Sep 30, 2025 | 2.93% |
| Jun 30, 2025 | -123.36% |
| Mar 31, 2025 | -4.05% |
| Dec 31, 2024 | 8.05% |
| Sep 30, 2024 | -2.14% |
| Jun 30, 2024 | -0.72% |
| Mar 31, 2024 | 1.07% |
| Dec 31, 2023 | 9.08% |
| Sep 30, 2023 | 6.95% |
| Jun 30, 2023 | 3.28% |
| Mar 31, 2023 | 9.55% |
| Dec 31, 2022 | 17.04% |
| Sep 30, 2022 | 16.89% |
| Jun 30, 2022 | 15.05% |
| Mar 31, 2022 | 12.26% |
| Dec 31, 2021 | 14.36% |
| Sep 30, 2021 | 14.59% |
| Jun 30, 2021 | 13.30% |